Protection of rat myocardium by mitogenic and non-mitogenic fibroblast growth factor during post-ischemic reperfusion
- PMID: 9401816
- DOI: 10.3109/08977199709002110
Protection of rat myocardium by mitogenic and non-mitogenic fibroblast growth factor during post-ischemic reperfusion
Abstract
The effects of acidic fibroblast growth factor (FGF-1) and basic fibroblast growth factor (FGF-2) and a non mitogenic form of FGF1 on myocardial ischemia and reperfusion were assessed. Rats underwent 10 minutes of coronary artery occlusion followed by 24 hours of reperfusion. Creatinine kinase content of the affected myocardium showed that both fibroblast growth factors 1 and 2 effectively protected against ischemia reperfusion injury (p < 0.01), and that the vasoactive but nonmitogenic form of the FGF1 was equally protective (p < 0.01 versus control + vehicle). The results were confirmed by light and electron-microscopy histological studies. Histological evaluations after treatment with the non-mitogenic fibroblast growth factor 1 showed that it did not generate the severe hyperplasia and connective tissue disorganization observed with the native mitogenic proteins. The possibility of using a non-mitogenic form of fibroblast growth factor for cardio-protection circumvents many of the potentially undesirable effects that may derive from systemically introducing broad spectrum acting fibroblast growth factors in vivo. This myocardial protection observed 24 hours after the treatment with fibroblast growth factors, and the efficacy of the non-mitogenic form of the protein, also suggest that the protective effect of fibroblast growth factors may be due to the increased blood flow rather than to angiogenesis.
Similar articles
-
Fibroblast growth factor-1 prevents myocardial apoptosis triggered by ischemia reperfusion injury.Eur J Med Res. 1997 Nov 28;2(11):465-8. Eur J Med Res. 1997. PMID: 9385115
-
Fibroblast growth factor cardioprotection against ischemia-reperfusion injury may involve K+ ATP channels.Eur J Med Res. 2000 Apr 19;5(4):145-9. Eur J Med Res. 2000. PMID: 10799348
-
Cardioprotection from ischemia by fibroblast growth factor: role of inducible nitric oxide synthase.Eur J Med Res. 1999 Dec 16;4(12):517-24. Eur J Med Res. 1999. PMID: 10611056
-
A non-mitogenic form of acidic fibroblast growth factor reduces neutrophil infiltration in rat ischemic reperfused heart.Eur J Med Res. 1997 Apr 21;2(4):139-43. Eur J Med Res. 1997. PMID: 9110918
-
Cardiovascular protection of nonmitogenic human acidic fibroblast growth factor from oxidative damage in vitro and in vivo.Cardiovasc Pathol. 2007 Mar-Apr;16(2):85-91. doi: 10.1016/j.carpath.2006.11.004. Epub 2007 Jan 5. Cardiovasc Pathol. 2007. PMID: 17317541
Cited by
-
Fibroblast growth factors in myocardial ischemia / reperfusion injury and ischemic preconditioning.J Cell Mol Med. 2001 Apr-Jun;5(2):132-42. doi: 10.1111/j.1582-4934.2001.tb00146.x. J Cell Mol Med. 2001. PMID: 12067496 Free PMC article. Review.
-
Dynamics of vascular growth factors after coronary angioplasty.Dokl Biol Sci. 2004 Jul-Aug;397:292-4. doi: 10.1023/b:dobs.0000039695.54669.59. Dokl Biol Sci. 2004. PMID: 15508577 No abstract available.
-
Relationships of growth factors, proinflammatory cytokines, and anti-inflammatory cytokines with long-term clinical results of autologous bone marrow mononuclear cell transplantation in STEMI.PLoS One. 2017 May 30;12(5):e0176900. doi: 10.1371/journal.pone.0176900. eCollection 2017. PLoS One. 2017. PMID: 28558042 Free PMC article.
-
Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction.Int J Nanomedicine. 2017 Sep 26;12:7103-7119. doi: 10.2147/IJN.S145799. eCollection 2017. Int J Nanomedicine. 2017. PMID: 29026304 Free PMC article.
-
Secretion without Golgi.J Cell Biochem. 2008 Apr 1;103(5):1327-43. doi: 10.1002/jcb.21513. J Cell Biochem. 2008. PMID: 17786931 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources